# Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine

> **NCT04799847** · PHASE1,PHASE2 · UNKNOWN · sponsor: **LintonPharm Co.,Ltd.** · enrollment: 161 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Catumaxomab

## Key facts

- **NCT ID:** NCT04799847
- **Lead sponsor:** LintonPharm Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-23
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-11-30
- **Target enrollment:** 161 (ESTIMATED)
- **Last updated:** 2023-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04799847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04799847, "Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04799847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*